Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study.

被引：1
|
作者：
Weickhardt, A. J.
Williams, D.
Lee, C.
Simes, J.
Murone, C.
Wilson, K.
Cummins, M.
Asadi, K.
Price, T. J.
Mariadason, J.
Tebbutt, N. C.
机构：
[1] Ludwig Inst Canc Res, Heidelberg, Vic, Australia
[2] Austin Hlth, Heidelberg, Vic, Australia
[3] ANZGOG, Camperdown, NSW, Australia
[4] Univ Sydney, Natl Hlth & Med Res Council Clin Trials Ctr, Sydney, NSW 2006, Australia
[5] NHMRC Clin Trials Ctr, Sydney, NSW, Australia
[6] Queen Elizabeth Hosp, Woodville, SA 5011, Australia
[7] Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia
[8] Austin Hosp, Ludwig Oncol Unit, Heidelberg, Vic 3084, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3531
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Single nucleotide polymorphisms (SNPs) in vascular endothelial growth factor (VEGF) family genes as predictive or prognostic biomarkers in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of the phase III MAX Inter study.
    Chionh, Fiona J. M.
    Gebski, Val
    Chueh, Anderly C.
    Al-Obaidi, Sheren J.
    Welckhardt, Andrew James
    Lee, Chee
    Williams, David S.
    Murone, Carmel
    Wilson, Kate
    Scott, Andrew Mark
    Simes, John
    Price, Timothy Jay
    Mariadason, John M.
    Tebbutt, Niall C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] Benefit from bevacizumab (BV) is independent of pretreatment plasma vascular endothelial growth factor-A (pl-VEGF) in patients (pts) with metastatic colorectal cancer (mCRC).
    Holden, SN
    Ryan, E
    Kearns, A
    Holmgren, E
    Hurwitz, H
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 259S - 259S
  • [3] Complex carbohydrates as a predictive marker in metastatic colorectal cancer (mCRC) cancer patients treated with a vascular endothelial growth factor (VEGF) inhibitor and chemotherapy.
    Martin, Petra
    Fennelly, David William
    Rudd, Pauline
    O'Donoghue, Diarmuid
    Sheahan, Kieran
    Nolan, Blathnaid
    O'Sullivan, Jacintha
    Stockmann, Henning
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] Functional SNPs in vascular endothelial growth factor (VEGF-A) and overall survival (OS) in bevacizumab-treated patients with metastatic colorectal cancer (mCRC).
    Murphy, Janet E.
    Liebman, Hannah M.
    Zhou, Qian
    Bote, Josiah T.
    Daskalova, Anastassia
    Hooshmand, Susanne M.
    Ryan, David P.
    Kulke, Matthew
    Christiani, David C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] Dual targeting of vascular endothelial growth factor-A (VEGF-A) and angiopoietins (Ang) without chemotherapy in metastatic colorectal cancer (mCRC): Results of the VENGEANCE study.
    Mooi, Jennifer
    Chong, Geoffrey
    Brown, Stephen
    Wong, Rachel
    Price, Timothy Jay
    Skrinos, Effie
    Tebbutt, Niall C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] Expression and correlation analysis of RegIV and vascular endothelial growth factors (VEGF-A and VEGF-C) in metastatic spinal tumors
    Zhang, Shuquan
    Zhao, Guanjie
    Zhao, Yi
    Gu, Rui
    Peng, Chuangang
    Pu, Zhe
    Wu, Minfei
    [J]. ONCOLOGY LETTERS, 2017, 13 (05) : 3517 - 3521
  • [7] Vascular endothelial growth factor (VEGF) receptor expression correlates with histologic grade and stage of colorectal cancer
    Hashim, Ali F.
    Al-Janabi, As'ad A.
    Mahdi, Liwaa H.
    Al-Toriahi, Kaswer M.
    Yasseen, Akeel A.
    [J]. LIBYAN JOURNAL OF MEDICINE, 2010, 5 : 1 - 4
  • [8] Association of baseline CEA, VEGF, and soluble VEGF receptor-2 with treatment outcomes in two randomized phase III trials of cediranib in metastatic colorectal cancer (mCRC)
    Schmoll, H.
    Hoff, P. M.
    Robertson, J. D.
    Pike, L.
    Morgan, S.
    Wilson, D.
    Juergensmeier, J. M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer
    Ishigami, SI
    Arii, S
    Furutani, M
    Niwano, M
    Harada, T
    Mizumoto, M
    Mori, A
    Onodera, H
    Imamura, M
    [J]. BRITISH JOURNAL OF CANCER, 1998, 78 (10) : 1379 - 1384
  • [10] Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer
    S-I Ishigami
    S Arii
    M Furutani
    M Niwano
    T Harada
    M Mizumoto
    A Mori
    H Onodera
    M Imamura
    [J]. British Journal of Cancer, 1998, 78 : 1379 - 1384
12345